This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Complementary Medicine -
The testosterone mimetic properties of icariin
Zhen-Bao Zhang, Qing-Tao Yang
Department of Urology, Second Affiliated Hospital, Shantou University Medical College, Shantou 515041, China
Abstract
Aim: To evaluate the testosterone mimetic properties of icariin.
Methods: Forty-eight healthy male Sprague-Dawley
rats at the age of 15 months were randomly divided into four groups with 12 rats each: the control group (C), the model
group (M), the icariin group (ICA) and the testosterone group (T). The reproductive system was damaged by
cyclophosphamide (intraperitoneal injection, 20 mg/kg·day) for 5 consecutive days for groups M, ICA and T, at the sixth day,
ICA (gastric gavage, 200 mg/kg·day) for the ICA group and sterandryl (subcutaneous injection, 5 mg/rat·day) for the T
group for 7 consecutive days, respectively. The levels of serum testosterone, luteinizing hormone (LH), follicle
stimulating hormone (FSH), serum bone Gla-protein (BGP) and tartrate-resistant acid phosphatase activity in serum
(StrACP) were determined. The histological changes of the testis and the penis were observed by microscope with
hematoxylin-eosin (HE) staining and terminal deoxynucleotidyl transferase biotin-dUTP-X nick end labeling (TUNEL),
respectively. Results: (1) Icariin improved the condition of reproductive organs and increased the circulating levels
of testosterone. (2) Icariin treatment also improved the steady-state serum BGP and might have promoted bone
formation. At the same time, it decreased the serum levels of StrACP and might have reduced the bone resorption. (3)
Icarrin suppressed the extent of apoptosis of penile cavernosal smooth muscle cells.
Conclusion: Icariin has testosterone mimetic properties and has therapeutic potential in the management of
hypoandrogenism. (Asian J Androl 2006 Sep; 8: 601_605 )
Keywords: andropause; partial androgen deficiency of the aging male; icariin; hypoandrogenism; testosterone; rats
Correspondence to: Dr Zhen-Bao Zhang, Department of Urology, Second Affiliated Hospital, Shantou University Medical College,
Shantou 515041, China.
Tel: +86-754-891-5622, Fax: +86-754-834-6543
E-mail: zbzhang@stu.edu.cn; yang2001tao@126.com
Received 2005-12-17 Accepted: 2006-03-18
DOI: 10.1111/j.1745-7262.2006.00197.x
1 Introduction
The terms, andropause, partial androgen deficiency of the aging male (PADAM) or late-onset hypogonadism
(LOH), describe a clinical entity which has been defined as a syndrome associated with advanced age. This syndrome
is characterized by a deficiency in serum testosterone levels that might result in significant alterations in the quality of
life and adversely affect the function of multiple organ systems [1]. Profound and diffuse alterations in the
reproductive endocrine function and bone metabolism are associated
with hypoandrogenism, and will result in a significant
decline of physical function and quality of life. Although reports indicate that testosterone supplement
therapy (TST) might be an effective way to manage this condition[1], TST has the risk of therapy, and there might be adverse
effects on the prostate and cardiovascular risk factors [2].
Icariin
(C33H40O15, molecular weight: 676.67) is a flavonoid isolated from the plant
Herba epimedii [3, 4], which has been used as a tonic drug in traditional Chinese medicine (TCM) for centuries [5]. Icariin, the main active
component of Herba epimedii, can improve erectile function [5, 6] and has properties of antifatigue, immunoregulatory
and liver function improving [7_9]. Also, it increases the weights of the pituitary gland, testis and epididymis and the
testosterone concentration in immature male rats, and has testosterone mimetic pro-perties [10_12]. It also stimulates
the differentiation of osteoblasts and increases the activity of alkaline phosphatase (ALP) and the expression of
I-collagen protein in rats and promotes bone formation [13, 14].
The aim of the present study was to evaluate the testosterone mimetic properties of icariin after short-term
cyclophosphamide treatment followed by icariin or testosterone treatment in male rats.
2 Materials and methods
2.1 Animals and groups
Forty-eight healthy male Sprague-Dawley rats aged 15 months, weighing 220_300 g, were obtained from the
Experimental Animal Centre of Shantou University Medical College. They were housed under standard conditions in a
controlled environment with a 12-h photoperiod and had free access to food and water. All rats were divided at random into
four groups with 12 rats each: the control group (C), the model group (M), the icariin group (ICA) and the testosterone
group (T).
2.2 Model building
It is reported that cyclophosphamide treatment results in a significant inhibition in activities of testicular
3b-hydroxysteroid dehydrogenase (3b-HSD) and 17b-hydroxysteroid dehydrogenase
(17b-HSD), a decrease in plasma testosterone level and a decrease in the counts of various germ cells [15]. According to our pre-experiment after
injecting cyclophosphamide (20 mg/kg·day) for 5 days [16, 17], compared with the control group, the treatment
group rats showed phenomena similar to PADAM, such as lowered bodyweight, reduced activity, kraurotic hair,
lowered testosterone level, reduced bone formation, increased bone sorption and accelerated degeneration of
reproductive organs, which indicated the success of the model. This model was used as the M group in the present study.
2.3 Experimental design
Nothing was administered to the C group. To the M, T and ICA groups,
cyclophosphamide was administered by intraperitoneal injection at a dose of 20 mg/kg·day for 5 consecutive days. At the sixth day, nothing was
admi-nistered to the M group, and sterandryl was administered by subcutaneous injection at a dose of 5 mg/rat·day for 7 consecutive days in the
T group, and icariin (40% purity momoside; Huacui Biotechnology, Xi¡¯an, China) was administered through gastric gavage at
a dose of 200 mg/kg·day for 7 consecutive days in the ICA group. Forty-eight rats were sacrificed under 0.3% pentobarital
sodium anesthesia, 24 hours after the last icariin and sterandryl treatment. Blood samples (4_5 mL)
were obtained from the heart. Serum samples were collected and stored at _70ºC for the determination of testosterone, luteinizing
hormone (LH), follicle stimulating hormone (FSH), serum bone Gla-protein (BGP) and tartrate-resistant acid
phosphatase activity in serum (StrACP). The testes, epididymis and seminal vesicles were dissected and weighed. The
left testis and the middle part of the penis were fixed in Bouin¡¯s fixative and embedded in paraffin wax.
Four-micrometer sections were cut off from the middle portion of the testis and penis, and stained with
hematoxylin-eosin (HE) and deoxynucleotidyl transferase biotin-dUDP-X nick end labeling (TUNEL).
2.4 Assessment of effects of ICA on reproduction endocrine function and bone metabolism
Serum testosterone, LH, FSH and BGP levels were determined by radioimmunoassay (RIA). The RIA kits were
provided by Beijing North Institute of Biological Products (Beijing, China). Serum StrACP was determined by
colorimetry [18]. The kit was provided by the Nanjing Jiancheng Institute of Biological Products (Nanjing, China).
2.5 Cell apoptosis determination
The apoptosis of cavernosal smooth muscle of the penis was determined by TUNEL. The kit was provided by
Wuhan Boster Institute of Biological Products (Wuhan, China). All procedures were carried out according to the kit
instructions. Cells exhibiting dark brown nuclear staining were considered apoptotic. Negative controls,
lacking the labeling enzyme, yielded no reaction product. All counting was carried out on a light microscope using × 400 magnification.
Ten visual fields were selected randomly and the average ratio of the number of apoptotic cells to the number of all cells
was considered apoptosis rate, that is to say, apoptosis rate = the number of apoptotic cells/the number of all cells.
2.6 Statistical analysis
The data were expressed as mean ± SD and analyzed by SPSS 10.0 statistical analytical software (SPSS, Chicago,
IL, USA). All two-group comparisons were made with unpaired
t-test. All multiple comparisons were made by
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. Differences were considered
significant when P < 0.05.
3 Results
3.1 Effect of icariin on reproductive organs
As shown in Table 1, the weights of the testis and the seminal vesicles in the C, ICA and T groups were statistically
higher than those in the M group. Furthermore, the weight of the seminal vesicles in the T group was statistically higher
than that in the ICA and C groups (P < 0.05).
3.2 Effect of icariin on reproduction endocrine function
Table 2 shows that in the C, ICA and T groups, the serum testosterone concentration was higher than that in the M
group. Furthermore, the concentration of serum testosterone in the ICA group was higher than that in the C group and
lower than that in the T group (P <
0.05). There were no significant differences in levels of LH and FSH among these
four groups.
3.3 Effect of icariin on osseous metabolism
As shown in Table 3, the levels of BGP in the ICA and T groups were statistically higher than those in the M and
C groups (P < 0.05). Whereas, the levels of StrACP in the C, ICA and T groups were statistically lower than those in
the M group (P < 0.05). Furthermore, the levels of StrACP in the ICA and T groups were lower than those in the C
group (P < 0.05).
3.3 Cell apoptosis determination
Table 4 shows that in the ICA and T groups, the apoptosis rate of the cavernosal smooth muscle cells in the penis
was lower than that in the M group (P < 0.05), and there was no statistical difference between the ICA group and the
T group.
4 Discussion
In the aging male, endocrine changes and a decline in endocrine function involve tissue responsiveness, reduced
secretory output from peripheral glands and alterations in the central mechanism controlling the temporal organization
of hormonal release [19]. Hypogonadism is a clinical condition in which low level
of serum testosterone is found in association with specific
signs and symptoms, including diminished libido and sense of
vitality, erectile dysfunction, reduced muscle mass and bone
density, depression and anemia. When hypogonadism occurs
in an older man, the condition is often called "late-onset-hypogonadism" or PADAM [20]. By restoring serum testosterone level to the
normal range using TST, many of these symptoms can be relieved [21]. Reports indicate that TST might produce a
wide range of benefits for men with
hypogonadism that include improvement in libido, bone density,
muscle mass, body composition, mood, erythropoiesis
and cognition [20]. In the present study, after the use of sterandryl in the T
group rats, the level of serum testosterone (34.9649 ± 11.4220 ng/mL) increased to the normal range of adult SD rat
(24.24_39.31 ng/mL[22]). However, TST has potential undesirable side effects. These concerns are primarily in
regards to liver, prostate, lipid profile and cardiovascular system, hematological changes, sleep patterns, social behavior
and emotional state [19]. Prostate disease, particularly
prostate cancer, and cardiovascular disease are the main
safety concerns [23]. Therefore, it is necessary to introduce new treatment drugs.
In the present study, we found that chronic treatment of chemically-induced hypoandrogenic male rats with
icariin improved the condition of reproductive organs and increased the circulating level of testosterone. We also
found that icariin suppressed the extent of apoptosis of penile cavernosal smooth muscle cells. It seems that icariin
possesses testosterone-like activities. However, in the present study, there was no significant difference in serum
levels of LH and FSH between ICA group and the others. It seems that icariin mainly affects the testis, but further
study is required.
BGP (also called osteocalcin) is the most abundant noncollagenous protein of the bone
matrix. It is a small protein (6 000
Da), and is specifically synthesized by the bone-forming cells_the osteoblasts
[24]. Studies comparing concentrations of BGP in serum with direct as
sessment of bone remodeling by iliac crest histomor-phometry have shown that this protein is a specific marker of
osteoblastic bone formation [25]. Tartrate-resistant acid phosphatase (TRAP) is a functional marker of osteoclasts
[26]. Its activity is positively correlated with the activity of osteoclasts. TRAP can be produced by osteoclasts and
secreted into the blood. So we can assess the activity of osteoclasts by determining the activity of TRAP in serum [27].
In the present study, we found that icariin treatment also improved the steady-state serum BGP and might have promoted
bone formation. At the same time, it decreased the serum levels of
StrACP and might have reduced bone resorption. Therefore, icariin treatment is beneficial to bone metabolism.
In summary, icariin shows testosterone mimetic properties, and has therapeutic potential in the management of
hypoandrogenism, which is encountered in most of the aging male population. Further experimental and clinical work
is required.
References
1 Hochreiter WW, Ackermann DK, Brutsch HP. Andropause. Ther Umsch 2005; 62: 821_6.
2 Francis RM. Androgen replacement in aging
men. Calcif Tissue Int 2001; 69: 235_8.
3 Liang HR, Vuorela P, Vuorela H, Hiltunen R. Isolation and immunomodulatory effect of flavonol glycosides from Epimedium
hunanense. Planta Med 1997; 63: 316_9.
4 Du Q, Xia M, Ito Y. Purification of icariin from the extract of Epimedium segittatum using high-speed counter-current chromatography.
J Chromatogr A 2002; 962: 239_41.
5 Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms
in castrated rats. Asian J Androl 2005; 7: 381_8.
6 Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM,
et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4
activities. Asian J Androl 2003; 5: 15_8.
7 Lee MK, Choi YJ, Sung SH, Shin DI, Kim JW, Kim YC. Antihepatotoxic activity of icariin, a major constituent of Epimedium
koreanum. Planta Med 1995; 61: 523_6.
8 He W, Sun H, Yang B, Zhang D, Kabelitz D. Immunoregulatory effects of the
Herba Epimediia glycoside icariin.
Arzneimittel-forschung 1995; 45: 910_3.
9 Niu R. Action of the drug Herba
Epimedii on testosterone of the mouse plasma and its accessory sexual organ before and after processing.
Zhongguo Zhong Yao Za Zhi 1989; 14: 530_2, 574.
10 Xiong YB. The study on the relation between icariin and gonad. J Tradit Chin Med 1995; 26 (Suppl): 98_9.
11 Xiong YB, ZHOU CH. The effect of extracts from
Herba Epimedii and Semen Cuscutae on the function of male reproduction. Chin Pharm
J 1994; 29: 89_91.
12 She BR, Qin DN, Yang YH, She YC. The comparative studies on male reproduction effects between flavonoidys from
Herba epimedii and flavonoids from Semen
Cuscutae. CJCM 2003; 6: 842_5.
13 Xie F, Wu CF, Lai WP, Yang XJ, Cheng PY, Yao XS,
et al. The osteoprotective effect
of Herba epimedii (HEP) extract in
vivo and in vitro. eCAM 2005; 2: 353_61.
14 Liu SC, Kong DJ, Zhao JS, Li E. Effects of icariin on the proliferation and differentiation of osteoblasts. Chinese J Basic Med TCM
2001; 7: 28_30.
15 Das UB, Mallick M, Debnath JM, Ghosh D. Protective effect of ascorbic acid on cyclophosphamide-induced testicular gametogenic
and androgenic disorders in male rats. Asian J Androl 2002; 4: 201_7.
16 Wang JF, Tian SC, Jia GR. Experimental studies on antiaging effects of seal kidney. Chinese J Marine Drugs 2002; 5: 34_6.
17 Xie JX, Li SQ, Li P. Effect of alcohol etract from Calotes versilor ( Dandin) on rat's sex hormone level in serum. JMPCM 2003; 9:
27_8.
18 Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ. Characterization and assay of tartrate-resistant acid phosphatase activity in
serum: potential use to assess bone resorption. Clin Chem 1987; 33: 458_62.
19 Lunenfeld B. Androgen therapy in the aging male. World J Urol 2003; 21: 292_305.
20 Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;
350: 482_92.
21 Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK,
et al. Testosterone replacement therapy: current trends and future
directions. Hum Reprod Update 2004; 10: 409_19.
22 Sun XZ, Deng CH, Guo HB, Liu JZ. Experimental study of allograft Leydig cells transplantation of animal model of PADAM.
Chinese J Androl 2005; 19: 9_11.
23 Liu PL, Swerdloff RS, Veldhuis JD. Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future
research and current practice recommendations. J Clin Endocrinol Metab 2004; 89: 4789_96.
24 Pastoureau P, Delmas PD. Measurement of serum bone gla-protein (BGP) in humans with an ovine BGP-based radioimmu-noassay,
Clin Chem 1990; 36: 1620_4.
25 Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ. Serum bone gamma carboxyglutamic acid-containing
protein in primary hyperparathyroidism and
in malignant hypercalcemia. Comparison with bone histomorphometry.
J Clin Invest 1986; 77: 985_91.
26 Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982; 34:
285_90.
27 Hou J, Cai GY, Yang X, Zhao YH. Serum TRAP levels in normal human beings. Chin J Osteoporos 1999; 5: 43.
|